SEARCH

SEARCH BY CITATION

References

  • Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE & Martínez JL (2011) The intrinsic resistome of Pseudomonas aeruginosa to β-lactams. Virulence 2: 144146.
  • Andersson DI (2011) Evolving promiscuously. P Natl Acad Sci USA 108: 11991200.
  • Andersson DI & Hughes D (2009) Gene amplification and adaptive evolution in bacteria. Annu Rev Genet 43: 167195.
  • Andersson DI & Hughes D (2011) Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol Rev doi: DOI: 10.1111/j.1574-6976.2011.00289.x. Epub ahead of print
  • Anonymous (2008) Recent trends in antimicrobial resistance among Streptococcus pneumoniae and Staphylococcus aureus isolates: the French experience. Euro Surveill 13: 19035.
  • Aparicio JR, Such J, Pascual S et al. (1999) Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J Hepatol 31: 277283.
  • Bal AM, Kumar A & Gould IM (2010) Antibiotic heterogeneity: from concept to practice. Ann NY Acad Sci 1213: 8191.
  • Baquero F (2001) Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resist Update 4: 93105.
  • Baquero F (2004) From pieces to patterns: evolutionary engineering in bacterial pathogens. Nat Rev Microbiol 2: 510518.
  • Baquero F (2011) The 2010 Garrod Lecture: the dimension of evolution in antibiotic resistance: ex unibus plurum et ex pluribus unum. J Antimicrob Chemoth 66: 16591672.
  • Baquero F & Cantón R (2009) Evolutionary biology of drug resistance. Antimicrobial Drug Resistance (MayersDL, ed), pp. 932. Humana Press, New York.
  • Baquero F & Negri MC (1997) Selective compartments for resistant microorganisms in antibiotic gradients. Bioessays 19: 731736.
  • Baquero F, Negri MC, Morosini MI & Blázquez J (1998) Selection of very small differences in bacterial evolution. Int Microbiol 1: 295300.
  • Bauernfeind A, Jungwirth R & Eberlein E (1995) Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Infection 23: 316321.
  • Benenson S, Cohen MJ, Block C, Stern S, Weiss Y & Moses AE (2009) Vancomycin-resistant enterococci in long-term care facilities. Infect Control Hosp Epidemiol 30: 786789.
  • Blázquez J (2003) Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin Infect Dis 37: 12011209.
  • Blázquez J, Morosini MI, Negri MC & Baquero F (2000) Selection of naturally occurring extended-spectrum TEM β-lactamase variants by fluctuating β-lactam pressure. Antimicrob Agents Ch 44: 21822184.
  • Blázquez J, Gómez-Gómez JM, Oliver A, Juan C, Kapur V & Martín S (2006) PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. Mol Microbiol 62: 8499.
  • Blondeau JM, Zhao X, Hansen G & Drlica K (2001) Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Ch 45: 433438.
  • Borg MA, Zarb P, Ferech M & Goossens HARMed Project Group (2008) Antibiotic consumption in southern and eastern Mediterranean hospitals: results from the ARMed project. J Antimicrob Chemoth 62: 830836.
  • Borg MA, Zarb P, Scicluna EA, Rasslan O, Gür D, Ben Redjeb S, Elnasser Z & Daoud Z (2010) Antibiotic consumption as a driver for resistance in Staphylococcus aureus and Escherichia coli within a developing region. Am J Infect Control 38: 212216.
  • Briales A, Rodríguez-Martínez JM, Velasco C, Díaz de Alba P, Domínguez-Herrera J, Pachón J & Pascual A (2011) In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC. Antimicrob Agents Ch 55: 12661269.
  • Brown D & Cantón R (2010) Bases for clinical categorization. Antibiogram (CoruvalinP, LeclerqR & RiceLB, eds), pp. 3745. Eska Publishing ASM Press, Portland, OR.
  • Brown EM & Nathwani D (2005) Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J Antimicrob Chemoth 55: 69.
  • Cantón R, Coque TM & Baquero F (2003a) Multi-resistant Gram-negative bacilli: from epidemics to endemics. Curr Opin Infect Dis 16: 315325.
  • Cantón R, Garcia-Castillo M, Morosini MI, Baquero MR, Oliver A & Baquero F (2003b) Mutant prevention concentration (MPC) of different antibiotics in mutator and non-mutator Pseudomonas aeruginosa populations from cystic fibrosis patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, September 2003, Abstract book, American Society for Microbiology (abstract A-1320).
  • Cantón R, Lode H, Graninger W & Milkovich G (2006) Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. Int J Antimicrob Ag 28 (suppl 2): S115S127.
  • Carratalà J, Fernández-Sevilla A, Tubau F, Domínguez MA & Gudiol F (1996) Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Ch 40: 503505.
  • Cassier P, Lallechère S, Aho S, Astruc K, Neuwirth C, Piroth L & Chavanet P (2011) Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case–control study in a French teaching hospital. Clin Microbiol Infec 17: DOI: DOI: 10.1111/j.1469-0691.2010.03349.x.
  • Chopra I, O'Neill AJ & Miller K (2003) The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Update 6: 137145.
  • Chung P, McNamara PJ, Campion JJ & Evans ME (2006) Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Ch 50: 29572965.
  • Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T & Høiby N (2010) Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 156: 11081119.
  • Clinical and Laboratory Standards Institute (2011) Performance Standards for Antimicrobial Susceptibility Testing; 21th Informational Supplement. CLSI Document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
  • Couce A & Blázquez J (2009) Side effects of antibiotics on genetic variability. FEMS Microbiol Rev 33: 531538.
  • Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26: 110.
  • Credito K, Kosowska-Shick K, McGhee P, Pankuch GA & Appelbaum PC (2010) Comparative study of the mutant prevention concentrations of oxifloxacin, levofloxacin, and gemifloxacin against pneumococci. Antimicrob Agents Ch 54: 673677.
  • Croisier D, Etienne M, Piroth L, Bergoin E, Lequeu C, Portier H & Chavanet P (2004) In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemoth 54: 640647.
  • Cui J, Liu Y, Wang R, Tong W, Drlica K & Zhao X (2006) The mutant selection window in rabbits infected with Staphylococcus aureus. J Infect Dis 194: 16011608.
  • D'Costa VM, McGrann KM, Hughes DW & Wright GD (2006) Sampling the antibiotic resistome. Science 311: 374377.
  • D'Costa VM, Griffiths E & Wright GD (2007) Expanding the soil antibiotic resistome: exploring environmental diversity. Curr Opin Microbiol 10: 481489.
  • Dong Y, Zhao X, Domagala J & Drlica K (1999) Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Ch 43: 17561758.
  • Dong Y, Zhao X, Kreiswirth BN & Drlica K (2000) Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Ch 44: 25812584.
  • Donlan RM & Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15: 167193.
  • Driffield K, Miller K, Bostock M, O'Neill AJ & Chopra I (2008) Increased mutability of Pseudomonas aeruginosa in biofilms. J Antimicrob Chemoth 61: 10531056.
  • Drlica K (2001) A strategy for fighting antibiotic resistance. ASM News 67: 2733.
  • Enne VI, Livermore DM, Stephens P & Hall LM (2001) Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357: 13251328.
  • European Committee on Antimicrobial Susceptibility Testing (2011) Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3. Available at http://www.eucast.org
  • Fantin B, Duval X, Massias L, Alavoine L, Chau F, Retout S, Andremont A & Mentré F (2009) Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis 200: 390398.
  • Ferran A, Dupouy V, Toutain PL & Bousquet-Mélou A (2007) Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin. Antimicrob Agents Ch 51: 41634166.
  • Ferran AA, Kesteman AS, Toutain PL & Bousquet-Mélou A (2009) Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model. Antimicrob Agents Ch 53: 33843390.
  • Firsov AA, Vostrov SN, Lubenko IY, Arzamastsev AP, Portnoy YA & Zinner SH (2004) ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemoth 54: 178186.
  • Firsov AA, Smirnova MV, Strukova EN, Vostrov SN, Portnoy YA & Zinner SH (2008) Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. Int J Antimicrob Ag 32: 488493.
  • Furtado GH, Perdiz LB, Onita JH, Wey SB & Medeiros EA (2010) Correlation between rates of carbapenem consumption and the prevalence of carbapenem-resistant Pseudomonas aeruginosa in a tertiary care hospital in Brazil: a 4-year study. Infect Control Hosp Epidemiol 31: 664666.
  • García-Castillo M, Del Campo R, Baquero F, Morosini MI, Turrientes MC, Zamora J & Cantón R (2011) Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients. Clin Microbiol Infec 17: 704711.
  • García-Migura L, Liebana E & Jensen LB (2007) Transposon characterization of vancomycin-resistant Enterococcus faecium (VREF) and dissemination of resistance associated with transferable plasmids. J Antimicrob Chemoth 60: 263268.
  • Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M & Fishman NO (2009) Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 30: 11801185.
  • Hall-Stoodley L, Costerton JW & Stoodley P (2004) Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2: 95108.
  • Hansen GT & Blondeau JM (2005) Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. J Chemother 17: 484492.
  • Hansen GT, Zhao X, Drlica K & Blondeau JM (2006) Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Ag 27: 120124.
  • Hassett DJ, Ma JF, Elkins JG et al. (1999) Quorum sensing in Pseudomonas aeruginosa controls expression of catalase and superoxide dismutase genes and mediates biofilm susceptibility to hydrogen peroxide. Mol Microbiol 34: 10821093.
  • Hayasaki Y, Itoh S, Kato M & Furuhama K (2006) Mutagenesis induced by 12 quinolone antibacterial agents in Escherichia coli WP2uvrA/pKM101. Toxicol In Vitro 20: 342346.
  • Høiby N, Bjarnsholt T, Givskov M, Molin S & Ciofu O (2010) Antibiotic resistance of bacterial biofilms. Int J Antimicrob Ag 35: 322332.
  • Homma T, Hori T, Sugimori G & Yamano Y (2007) Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. Antimicrob Agents Ch 51: 38103815.
  • Hsueh PR, Chen WH & Luh KT (2005a) Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991–2003 at a university hospital in Taiwan. Int J Antimicrob Ag 26: 463472.
  • Hsueh PR, Chen WH, Teng L.J & Luh KT (2005b) Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Ag 26: 4349.
  • International Organization for Standardization (ISO) (2006) Clinical laboratory testing and in vitro diagnostic test systems – susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices – part 1: reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. International Standard 20776-1, ISO, Geneva.
  • Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Mouton JW, Osterlund A, Rodloff A, Steinbakk M, Urbaskova P & Vatopoulos A (2003) European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemoth 52: 145148.
  • Kohanski MA, DePristo MA & Collins JJ (2010) Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell 37: 311320.
  • Lee SO, Lee ES, Park SY, Kim SY, Seo YH & Cho YK (2004) Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 25: 832837.
  • Lepelletier D, Cady A, Caroff N, Marraillac J, Reynaud A, Lucet JC & Corvec S (2010) Imipenem-resistant Pseudomonas aeruginosa gastrointestinal carriage among hospitalized patients: risk factors and resistance mechanisms. Diagn Microbiol Infect Dis 66: 16.
  • Levin BR & Udekwu KI (2010) Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments. Antimicrob Agents Ch 54: 34143426.
  • Levy S (1997) Antibiotic resistance: an ecological imbalance. Antibiotic Resistance:Origins, Evolution, Selection and Spread. Ciba Foundation Symposium 207, pp. 114.
  • Lewis K (2010) Persister cells. Annu Rev Microbiol 64: 357372.
  • López D, Vlamakis H & Kolter R (2010) Biofilms. Cold Spring Harb Perspect Biol 2: a000398.
  • López E & Blázquez J (2009) Effect of subinhibitory concentrations of antibiotics on intrachromosomal homologous recombination in Escherichia coli. Antimicrob Agents Ch 53: 34113415.
  • López E, Elez M, Matic I & Blázquez J (2007) Antibiotic-mediated recombination: ciprofloxacin stimulates SOS-independent recombination of divergent sequences in Escherichia coli. Mol Microbiol 64: 8393.
  • Luo Y, Li J, Meng Y, Ma Y, Hu C, Jin S, Zhang Q, Ding H & Cui S (2011) Joint effects of topoisomerase alterations and plasmid-mediated quinolone-resistant determinants in Salmonella enterica Typhimurium. Microb Drug Resist 17: 15.
  • Macgowan APon behalf of the BSAC Working Parties on Resistance Surveillance (2008) Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemoth 62 (suppl 2): ii105ii114.
  • Maciá MD, Blanquer D, Togores B, Sauleda J, Pérez JL & Oliver A (2005) Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Ch 49: 33823386.
  • MacKenzie FM, Bruce J, Struelens MJ, Goossens H, Mollison J & Gould IMARPAC Steering Group (2007) Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals. Clin Microbiol Infec 13: 269276.
  • Mai-Prochnow A, Lucas-Elio P, Egan S, Thomas T, Webb JS, Sanchez-Amat A & Kjelleberg S (2008) Hydrogen peroxide linked to lysine oxidase activity facilitates biofilm differentiation and dispersal in several Gram-negative bacteria. J Bacteriol 190: 54935501.
  • Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE & Høiby N (2009) Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob Agents Ch 53: 24832491.
  • Martínez JL & Baquero F (2002) Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev 15: 647679.
  • Martínez-Solano L, Macia MD, Fajardo A, Oliver A & Martinez JL (2008) Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis 47: 15261533.
  • Masterton RG (2010) Antibiotic heterogeneity. Int J Antimicrob Agents 36 (suppl 3): S15S8.
  • Meyer E, Lapatschek M, Bechtold A, Schwarzkopf G, Gastmeier P & Schwab F (2009) Impact of restriction of third generation cephalosporins on the burden of third generation cephalosporin resistant K. pneumoniae and E. coli in an ICU. Intens Care Med 35: 862870.
  • Meyer E, Schwab F, Schroeren-Boersch B & Gastmeier P (2010) Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit Care 14: R113 doi: DOI: 10.1186/cc9062.
  • Meyer KS, Urban C, Eagan JA, Berger BJ & Rahal JJ (1993) Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 119: 353358.
  • Molin S & Tolker-Nielsen T (2003) Gene transfer occurs with enhanced efficiency in biofilms and induces enhanced stabilisation of the biofilm structure. Curr Opin Biotech 14: 255261.
  • Monnet DL, MacKenzie FM, López-Lozano JM, Beyaert A, Camacho M, Wilson R, Stuart D & Gould IM (2004) Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000. Emerg Infect Dis 10: 14321441.
  • Morosini MI, García-Castillo M, Coque TM, Valverde A, Novais A, Loza E, Baquero F & Cantón R (2006) Antibiotic coresistance in extended-spectrum-β-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Ch 50: 26952699.
  • Mouton JW (2002) Breakpoints: current practice and future perspectives. Int J Antimicrob Ag 19: 323331.
  • Mouton JW, Ambrose PG, Cantón R, Drusano GL, Harbarth S, Macgowan A, Theuretzbacher U & Turnidge J (2011) Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Update 14: 107117.
  • Mulcahy LR, Burns JL, Lory S & Lewis K (2010) Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 192: 61916199.
  • Negri MC, Lipsitch M, Blázquez J, Levin BR & Baquero F (2000) Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance. Antimicrob Agents Chemother 44: 24852491.
  • Negri MC, Morosini MI, Loza E & Baquero F (1994) In vitro selective antibiotic concentrations of ß-lactams for penicillin-resistant S. pneumoniae populations. Antimicrob Agents Ch 38: 122125.
  • Novais A, Comas I, Baquero F, Cantón R, Coque TM, Moya A, González-Candelas F & Galán JC (2010) Evolutionary trajectories of β-lactamase CTX-M-1 cluster enzymes: predicting antibiotic resistance. PLoS Pathog 6: e1000735.
  • Oliver A & Mena A (2010) Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. Clin Microbiol Infec 16: 798808.
  • Oliver A, Cantón R, Campo P, Baquero F & Blázquez J (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288: 12511254.
  • Oliver A, Sánchez JM & Blázquez J (2002) Characterization of the GO system of Pseudomonas aeruginosa. FEMS Microbiol Lett 217: 3135.
  • Olofsson SK, Marcusson LL, Komp Lindgren P, Hughes D & Cars O (2006) Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemoth 57: 11161121.
  • Pallecchi L, Bartoloni A, Paradisi F & Rossolini GM (2008) Antibiotic resistance in the absence of antimicrobial use: mechanisms and implications. Expert Rev Anti Infect Ther 6: 725732.
  • Pasquali F & Manfreda G (2007) Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa. Vet Microbiol 119: 304310.
  • Peirano G & Pitout JD (2010) Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Ag 35: 316321.
  • Plasencia V, Borrell N, Maciá MD, Moya B, Pérez JL & Oliver A (2007) Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. Antimicrob Agents Ch 51: 25742581.
  • Polk RE, Johnson CK, McClish D, Wenzel RP & Edmond MB (2004) Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 39: 497503.
  • Prelog M, Grif K, Decristoforo C, Würzner R, Kiechl-Kohlendorfer U, Brunner A, Zimmerhackl LB & Orth D (2009) Tetracycline-resistant Escherichia coli strains are inherited from parents and persist in the infant's intestines in the absence of selective pressure. Eur J Pediatr 168: 11811187.
  • Rahal JJ, Urban C & Segal-Maurer S (2002) Nosocomial antibiotic resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis 34: 499503.
  • Rodríguez-Baño J & Pascual A (2008) Clinical significance of extended-spectrum β-lactamases. Expert Rev Anti Infect Ther 6: 671683.
  • Rodríguez-Martínez JM, Velasco C, García I, Cano ME, Martínez-Martínez L & Pascual A (2007) Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1. Antimicrob Agents Ch 51: 22362239.
  • Rodríguez-Rojas A & Blázquez J (2009) The Pseudomonas aeruginosapfpI gene plays an antimutator role and provides general stress protection. J Bacteriol 191: 4450.
  • Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K & Huovinen P (1997) The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. New Engl J Med 337: 441446.
  • Shryock TR & Richwine A (2010) The interface between veterinary and human antibiotic use. Ann NY Acad Sci 1213: 92105.
  • Sierra JM, Cabeza JG, Ruiz Chaler M, Montero T, Hernandez J, Mensa J, Llagostera M & Vila J (2005) The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clin Microbiol Infec 11: 750758.
  • Smania AM, Segura I, Pezza RJ, Becerra C, Albesa I & Argaraña CE (2004) Emergence of phenotypic variants upon mismatch repair disruption in Pseudomonas aeruginosa. Microbiology 150: 13271338.
  • Speziale P, Visai L, Rindi S, Pietrocola G, Provenza G & Provenzano M (2008) Prevention and treatment of Staphylococcus biofilms. Curr Med Chem 15: 31853195.
  • Sundqvist M, Geli P, Andersson DI, Sjölund-Karlsson M, Runehagen A, Cars H, Abelson-Storby K, Cars O & Kahlmeter G (2010) Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J Antimicrob Chemoth 65: 350360.
  • Sykes R (2010) The 2009 Garrod lecture: the evolution of antimicrobial resistance: a Darwinian perspective. J Antimicrob Chemoth 65: 18421852.
  • Tam VH, Louie A, Deziel MR, Liu W, Leary R & Drusano GL (2005) Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis 192: 420428.
  • Tam VH, Louie A, Deziel MR, Liu W & Drusano GL (2007) The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Ch 51: 744747.
  • Tamma PD & Cosgrove SE (2011) Antimicrobial stewardship. Infect Dis Clin N Am 25: 245260.
  • Tängdén T, Eriksson BM, Melhus A, Svennblad B & Cars O (2011) Radical reduction of cephalosporin use at a tertiary hospital after educational antibiotic intervention during an outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae. J Antimicrob Chemoth 66: 11611167.
  • Thi TD, López E, Rodríguez-Rojas A, Rodríguez-Beltrán J, Couce A, Guelfo JR, Castañeda-García A & Blázquez J (2011) Effect of recA inactivation on mutagenesis of Escherichia coli exposed to sublethal concentrations of antimicrobials. J Antimicrob Chemoth 66: 531538.
  • Turnidge J & Paterson DL (2007) Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20: 391408.
  • Valderrey AD, Pozuelo MJ, Jiménez PA, Maciá MD, Oliver A & Rotger R (2010) Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. Diagn Microbiol Infect Dis 68: 2027.
  • Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F & Cantón R (2004) Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 42: 47694775.
  • Valverde A, Grill F, Coque TM, Pintado V, Baquero F, Cantón R & Cobo J (2008) High rate of intestinal colonization with extended-spectrum-β-lactamase-producing organisms in household contacts of infected community patients. J Clin Microbiol 46: 27962799.
  • van Loon HJ, Vriens MR, Fluit AC, Troelstra A, van der Werken C, Verhoef J & Bonten MJ (2005) Antibiotic rotation and development of gram-negative antibiotic resistance. Am J Resp Crit Care 171: 480487.
  • Weng TC, Chen YH, Lee CC, Wang CY, Lai CC, Tang HJ, Ko WC & Hsueh PR (2011) Correlation between fluoroquinolone consumption in hospitals and ciprofloxacin resistance amongst Pseudomonas aeruginosa isolates causing healthcare-associated infections, Taiwan, 2000–2009. Int J Antimicrob Ag 37: 581584.
  • Yang L, Haagensen JAJ, Jelsbak L, Johansen HK, Sternberg C, Høiby N & Molin S (2008) In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infection. J Bacteriol 190: 27672776.
  • Zhanel GG, Mayer M, Laing N & Adam HJ (2006) Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Ch 50: 222830.
  • Zhao X & Drlica K (2008) A unified anti-mutant dosing strategy. J Antimicrob Chemoth 62: 434436.
  • Zhao X, Eisner W, Perl-Rosenthal N, Kreiswirth B & Drlica K (2003) Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Ch 47: 10231027.